

Novogen Ltd

08:43 14 Nov 2017

Novogen signs agreement to facilitate brain cancer clinical trials in China

Novogen Limited (ASX:NRT) has entered into an agreement with Cedrus Investments Ltd for advisory services to establish a corporate structure focused on the Greater China region.

Novogen is an emerging oncology-focused biotechnology company, based in Sydney.

The new corporate entity will enable Novogen to interact directly with the Chinese Food and Drug Administration (CFDA) for future clinical trials in China.

The agreement defines the key terms, with most of the work expected to be conducted in the first half of calendar 2018.

It is also expected that the Chinese entity will be a Wholly Foreign Owned Enterprise (WFOE), headquartered in Shanghai.

Novogen is developing GDC-0084, a novel targeted therapy that modulates the PI3K pathway to treat glioblastoma multiforme (GBM).

GBM is the most common and most aggressive form of brain cancer.

Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials this year.

Novogen has several preclinical programs in active development, the largest of which is substantially funded by a CRC-P grant from the Australian Federal Government.

The partnership with Cedrus Investments will help Novogen to engage with researchers and investors to support the development of its current and future pipeline.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

1 Year Share Price Graph



Share Information

Code: NRT
Listing: ASX
Sector: Pharma & Biotech
Website: www.novogen.com

Company Synopsis:

Novogen Ltd (ASX:NRT, NASDAQ:NVGN) is listed on the Australian Securities Exchange.

Author:

Proactive Investors Australia
+61 (0)2 9280 0700
action@proactiveinvestors.com.au

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.